Drug intelligence / Profile preview

STX1200

Development stage: Preclinical
Lead developer: Scribe Therapeutics
Modality: Gene Editing → Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous (based On Standard For LNP-delivered Gene Editors; Preclinical Data Used Iv Administration[5])

Overview

STX1200 is a gene editing therapeutic candidate developed by Scribe Therapeutics targeting the LPA gene (Lipoprotein(a)). It is designed as a lysophosphatidic acid (LPA) modulator for the treatment of lipoprotein(a) hyperlipoproteinemia. Preclinical studies have demonstrated that STX1200 can achieve high-efficiency hepatocyte editing and substantially reduce serum Apo(a) protein levels (>90%) in transgenic mouse models. The drug utilizes lipid nanoparticle (LNP) delivery to target liver cells and has shown minimal off-target effects in primary human hepatocytes[1][5].

Targets

LPA (Lysophosphatidic acid)

Beyond the preview

Go deeper on STX1200.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STX1200.

Explore the full profile